Education
About Us
Working with TipRanks
Follow Us
BioArctic AB Class B (SE:BIOA.B)
:BIOA.B
BIOA.B Stock Chart & Stats
kr309.60
-kr0.60(-0.27%)
At close: 4:00 PM EST
kr309.60
-kr0.60(-0.27%)
Day’s Range― - ―
52-Week Rangekr154.40 - kr364.40
Previous CloseN/A
Volume25.17K
Average Volume (3M)142.19K
Market Cap
kr32.30B
Enterprise Valuekr29.96B
Total Cash (Recent Filing)kr2.19B
Total Debt (Recent Filing)kr72.42M
Price to Earnings (P/E)30.2
Beta0.19
Next Earnings
May 20, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding74,241,486
10 Day Avg. Volume198,890
30 Day Avg. Volume142,190
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)13.99
Price to Sales (P/S)13.76
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
2025 Profitability InflectionA sharp 2025 margin improvement signals materially stronger earnings power if sustained. Very high gross and net margins increase operating leverage, enabling more cash retention from revenue advances and improving ability to fund R&D or support partner milestones over the medium term.
Conservative Balance SheetA low debt load and growing equity base provide financial flexibility to fund development and absorb setbacks without immediate refinancing pressure. This supports a research-heavy biotech model and reduces bankruptcy risk, making strategic partnerships and milestone investments more durable.
Partnering-Based Revenue ModelA licensing-and-partnership model lets BioArctic concentrate on early R&D while transferring late-stage development, manufacturing, and commercialization costs to partners. This capital-light approach can sustainably scale returns via milestones and royalties without large internal commercialization investments.
Bears Say
Free Cash Flow UncertaintyZero FCF in 2025 despite operating cash rebound highlights uncertain cash left after investments. Inconsistent historical FCF (negative in multiple years) raises risk that future R&D or milestone timing will force external financing or constrain strategic optionality over the medium term.
Earnings VolatilityLarge year-to-year swings suggest revenue and profitability are driven by milestone timing rather than stable recurring cash flows. That structural volatility makes multi-quarter planning harder, increases refinancing and investor confidence risks, and can magnify downside if key milestones slip.
Concentration On Key Partner/ProductHeavy reliance on a single partner and product creates concentration risk: regulatory, commercial, or contractual setbacks at the partner can sharply reduce revenue and royalties. Limited commercial independence means BioArctic's medium-term revenue trajectory is tied to partner execution.
BioArctic AB Class B News
BIOA.B FAQ
What was BioArctic AB Class B’s price range in the past 12 months?
BioArctic AB Class B lowest stock price was kr154.40 and its highest was kr364.40 in the past 12 months.
What is BioArctic AB Class B’s market cap?
BioArctic AB Class B’s market cap is kr32.30B.
When is BioArctic AB Class B’s upcoming earnings report date?
BioArctic AB Class B’s upcoming earnings report date is May 20, 2026 which is in 88 days.
How were BioArctic AB Class B’s earnings last quarter?
BioArctic AB Class B released its earnings results on Feb 18, 2026. The company reported -kr0.1 earnings per share for the quarter, beating the consensus estimate of -kr0.54 by kr0.44.
Is BioArctic AB Class B overvalued?
According to Wall Street analysts BioArctic AB Class B’s price is currently Overvalued.
Does BioArctic AB Class B pay dividends?
BioArctic AB Class B pays a Notavailable dividend of kr1.5 which represents an annual dividend yield of N/A. See more information on BioArctic AB Class B dividends here
What is BioArctic AB Class B’s EPS estimate?
BioArctic AB Class B’s EPS estimate is -0.23.
How many shares outstanding does BioArctic AB Class B have?
BioArctic AB Class B has 74,241,486 shares outstanding.
What happened to BioArctic AB Class B’s price movement after its last earnings report?
BioArctic AB Class B reported an EPS of -kr0.1 in its last earnings report, beating expectations of -kr0.54. Following the earnings report the stock price went up 12.4%.
Which hedge fund is a major shareholder of BioArctic AB Class B?
Currently, no hedge funds are holding shares in SE:BIOA.B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioArctic AB Class B
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---